APA (7th ed.) Citation

Eickhoff, R., Pons, M., Kochen, L., Vortmeyer, D., Al-Batran, S., Habibzade, T., . . . Modest, D. P. (2024). ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer. Journal of clinical oncology, 42(3_suppl), TPS583. https://doi.org/10.1200/JCO.2024.42.3_suppl.TPS583

Chicago Style (17th ed.) Citation

Eickhoff, Regina, et al. "ADJUBIL: A Phase II Study of Immunotherapy with Durvalumab and Tremelimumab in Combination with Capecitabine or Without Capecitabine in Adjuvant Situation for Biliary Tract Cancer." Journal of Clinical Oncology 42, no. 3_suppl (2024): TPS583. https://doi.org/10.1200/JCO.2024.42.3_suppl.TPS583.

MLA (9th ed.) Citation

Eickhoff, Regina, et al. "ADJUBIL: A Phase II Study of Immunotherapy with Durvalumab and Tremelimumab in Combination with Capecitabine or Without Capecitabine in Adjuvant Situation for Biliary Tract Cancer." Journal of Clinical Oncology, vol. 42, no. 3_suppl, 2024, p. TPS583, https://doi.org/10.1200/JCO.2024.42.3_suppl.TPS583.